

TruScreen Key Investment Highlights

TruScreen (NZX:TRU) provides an accurate, real time cervical cancer primary screening solution for Low and Middle-Income Countries (LMICs). Our solution is affordable, easy to learn, and ideal for communities that cannot access conventional laboratory-enabled screening methods. TruScreen's purpose is to ensure that all women of screening age – no matter who they are – can have access to quality screening.

Disruptive technology, high potential

- ▶ NZD 166M addressable market p.a.¹
- ▶ Real-time, single visit, mobile screening technology
- ▶ No Laboratory infrastructure required, nurse administered

Attractive commercial model

- ▶ Ramping up in existing markets to deliver sales growth
- ▶ Introducing manufacturing process enhancements to deliver double-digit margin improvement

Clinical and commercial validation

- ▶ Accuracy equal to, or better, than alternative screening methods
- ▶ Established user base and Key Opinion Leader (KOL) support in key markets

Poised for growth

- ▶ Targeting large LMIC markets
- ▶ Lean distributor-based model
- ▶ Annuity revenue stream

Capital Raise Offer Details

TruScreen is seeking to raise a maximum of NZ\$1.5m through a same class offer to New Zealand investors.

The Offer comprises:

- ▶ A priority allocation of \$1 million of new TRU shares (at an issue price of \$0.05 per share) to an NZX market participant; and

- ▶ A public pool of \$500,000 of new TRU shares (at an issue price of \$0.05 per share), which is open to both New Zealand retail and wholesale investors. In the event that oversubscriptions are received in respect of the public pool, those subscriptions will be scaled on a pro rata basis. Any shares not taken up in the priority allocation may be reallocated to the public pool.

Cervical Cancer Is A Major Public Health Issue

Fourth most common cancer affecting women worldwide

- ▶ **570,000** new cases each year
- ▶ **311,000** deaths annually

Cervical Cancer is a preventable disease

Young women in Low and Middle-income countries (LMICS) are most at risk

- ▶ Most diagnoses occur at **age 35-44**
- ▶ **85%** of cases and **87%** of deaths occur in LMICS

1BN+ women of screening age in LMICS

World Health Organisation (WHO) has set a target to eliminate cervical cancer by the end of the century by targeting:



90% coverage of HPV Vaccination of girls



Better management of **90%** of invasive cancer cases



70% coverage of screening and **90%** treatment of precancerous lesions




TruScreen contributing to WHO's **70%** screening target

¹ Based on TruScreen achieving 5 per cent market share of developing markets' cervical cancer screening age population screened once every three years

TruScreen Business Model

TruScreen

- ▶ Sustainable recurring revenue model
- ▶ Single Use Sensor (SUS) creates annuity revenue
- ▶ Co-investment model with distributors, lean organizational structure



End customer

TruScreen's distributors target:

- ▶ Public hospitals
- ▶ Private hospitals
- ▶ Public health initiatives
- ▶ Governments
- ▶ Non-Government Organisations

Commercial Snapshot

Key Market – China

- ▶ TruScreen's largest market (57% of sales)
- ▶ World's largest cervical cancer market - 401m women of screening age
- ▶ First distribution agreements signed in 2014
- ▶ Pilot program of 20,000 women with Centre for Disease Control (CDC)
- ▶ SUS usage in hospitals: Up to 1,000 per month

FY20 Snapshot – Unaudited

- ▶ FY20 Sales NZ\$1.3m
- ▶ Total Revenue NZ\$2.5m
- ▶ Chinese market on road to recovery post COVID-19
- ▶ Initiated major SUS cost reduction project which will see significant increase in Gross Profit

Executive Team

Victoria Potarina, Chief Executive Officer
Guy Robertson, Chief Financial Officer
Dr. Jerry Tan, GM international BD
Paul Curran, GM Quality & Regulatory Compliance

Key Financial Details

As at 15 May 2020

Market Cap: NZ\$16.2M
 Share Price: NZ\$0.071
 Cash Position: NZ\$1M (as at 31 March 2020).

***A capital raising closed on May 15, 2020, which raised NZ\$3.743m.**

INVESTOR CONTACT

guyrobertson@truscreen.com

This fact sheet should be viewed in conjunction with TruScreen's latest Financial information and any accompanying NZX releases. The information presented is a snapshot and does not contain supporting information necessary to make an investment decision. It is not intended to act as a recommendation to acquire TruScreen shares. There can be no assurance that actual outcomes will not materially differ from the forward looking statements presented. A number of important factors could cause actual results or performance to differ materially from the forward-looking statements. The forward-looking statements are based on information available to TruScreen as at the date of this fact sheet. Except as required by law (including the NZX Listing Rules), TruScreen undertakes no obligation to provide any additional or updated information whether as a result of new information, future events or results or otherwise. TruScreen, its advisers, affiliates, related bodies corporate, directors, officers, partners, employees and agents make no representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of information in this fact sheet.